Intention

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

Retrieved on: 
Thursday, June 30, 2022 - 3:00am
Patient, Research, TSX, GLOBE, Marketing, Growth, Company, Psilocybin, Mission statement, Spinout, Family, Drug development, Patent, Contract research organization, Efficiency, Depreciation, TSX Venture Exchange, Nasdaq, Travel, Exercise, Association, Pharmacokinetics, Wellness, Field trip, Concurrency, Intention, International Financial Reporting Standards, Acquisition, IAS, CEO, Ketamine, Lists of diseases, Substance abuse, DC, Toronto Stock Exchange, CRO, IFRS, NASDAQ, Board, Mental health, Drug discovery, Method, Anxiety, International, R, Depression, 1836 U.S. Patent Office fire, District, Reunion, PAT, Safety, Home Power, Pharmaceutical industry, Online gambling, Security (finance), Management, BC, Arrangement

In May, 2022, launched Field Trip at Home Powered by Nue Life, an advanced wellness platform for personalized, at-home psychedelic care.

Key Points: 
  • In May, 2022, launched Field Trip at Home Powered by Nue Life, an advanced wellness platform for personalized, at-home psychedelic care.
  • TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported fiscal fourth quarter and full year 2022 results for the period ended March 31, 2022 and provided a business update.
  • Post quarter end, Field Trip announced the completion of its previously announced strategic review and the intention to complete a reorganization that will separate the Field Trip Discovery and Field Trip Health Divisions into two independent public companies (the Spinout Transaction).
  • Throughout the fiscal fourth quarter, the Company continued to implement operational improvements to reduce costs and increase throughput at its Field Trip Health Centers.

CBD Global Issues Fourth Bi-Weekly Report and Provides Update on Delayed Annual Filings

Retrieved on: 
Wednesday, June 29, 2022 - 11:00pm
Direct store delivery, OTC, Default, CEO, CGMP, DSD, Legislation, Alberta Securities Commission, Annual, GLOBE, Failure, Cannabidiol, Company, Industry, CSE, Forward-looking statement, CBDN, Corporation, CFO, NP, Annual Filing Season Program, Mission statement, THE, National Policy, Global Science Opera, CO, THIS, Hydration, Fortnight, News, Intention, Drug Master File, Security (finance), Bank, CBD

As previously announced in the Corporations press releases, the Corporation applied for and was granted a management cease trade order in respect of the delayed Annual Filings (the "MCTO") by the Alberta Securities Commission.

Key Points: 
  • As previously announced in the Corporations press releases, the Corporation applied for and was granted a management cease trade order in respect of the delayed Annual Filings (the "MCTO") by the Alberta Securities Commission.
  • The MCTO does not affect the ability of the general investing public to trade in the Corporations securities.
  • Global Sciences, Inc., is a hemp-based CBD producer and branding investment vehicle which currently owns two brands, branded under the name Aethics (www.aethics.com) and CANNAOIL, which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals, Hydration products and Confectionary products.
  • CBD Global Sciences hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.

Cytokinetics Announces Proposed Convertible Senior Notes Offering

Retrieved on: 
Wednesday, June 29, 2022 - 9:35pm
Patient, Securities Act of 1933, Securities Exchange Act of 1934, HCM, GLOBE, Growth, Sale, Metabolism, U.S. Securities and Exchange Commission, Forward-looking statement, Heart failure, SAN, Risk, Hypertrophic cardiomyopathy, SEC, Time, SEC Rule 144A, Intention, Security (finance), Pharmaceutical industry, Cytokinetics

The notes will be senior, unsecured obligations of Cytokinetics and will accrue interest payable semi-annually in arrears.

Key Points: 
  • The notes will be senior, unsecured obligations of Cytokinetics and will accrue interest payable semi-annually in arrears.
  • The notes will mature on July 1, 2027, unless earlier converted, redeemed or repurchased by Cytokinetics.
  • Cytokinetics intends to use a portion of the net proceeds from the offering and to issue shares of its common stock to repurchase a portion of its outstanding 4.00% convertible senior notes due 2026 (the 2026 notes) through privately negotiated transactions entered into concurrently with the pricing of the offering.
  • Cytokinetics may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding the final terms of the offering or the notes or its ability to effectively apply the net proceeds as described above.

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

Retrieved on: 
Wednesday, June 29, 2022 - 9:05pm
Weight gain, Oncology, CORT, Clinical Oncology, Patient, Probability, GLOBE, COVID-19, Union, Progression-free survival, Ovarian cancer, Disease, Goal, Intellectual property, Pancreatic cancer, Immune system, Publication, Woman, Liver disease, Cancer, Food, Doctor of Pharmacy, GR, Survival, SEC, NASDAQ, Paralympic record progression track cycling – Women's 1 km time trial, Recurrence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intention, Pharmaceutical industry, Medical imaging, Hospital, Corcept Therapeutics

The 20,000 women in the United States and an equal number in Europe with platinum-resistant ovarian cancer have few good treatment options.

Key Points: 
  • The 20,000 women in the United States and an equal number in Europe with platinum-resistant ovarian cancer have few good treatment options.
  • ROSELLA has a planned enrollment of 360 women with recurrent, platinum-resistant ovarian cancer, randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel monotherapy.
  • Additional information about ROSELLA and Corcepts Phase 2 trial results can be found at the publications and press releases tabs of www.corcept.com.
  • Corcept is studying relacorilant in a variety of serious disorders, including ovarian and adrenal cancer and Cushings syndrome.

BIGG Digital Assets Inc. Subsidiary Netcoins Launches Four New Digital Assets: ADA, SOL, DOT and GALA

Retrieved on: 
Wednesday, June 29, 2022 - 7:03pm
SEDAR, Heart, Comment, Intelligence, Failure, Law enforcement, Sale, CSE, Press release, Compliance, Environment, Technology, Semantic Web, Safety, Nature, Intention, Forward-looking statement, Cryptocurrency, Online shopping, Metaverse, Blockchain

About BIGG Digital Assets Inc.

Key Points: 
  • About BIGG Digital Assets Inc.
    BIGG Digital Assets Inc. (BIGG) believes the future of crypto is a safe, compliant, and regulated environment.
  • BIGG has four portfolio companies: Netcoins (netcoins.ca), Blockchain Intelligence Group (blockchaingroup.io), TerraZero (terrazero.com) and Luxxfolio (luxxfolio.com).
  • Netcoins utilizes BitRank Verified software at the heart of its platform and facilitates crypto trading via a self-serve crypto brokerage portal at Netcoins.app.
  • Additionally, BIGG undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

Traccom Inc. Announces Signing of Supply Agreement Letter of Intent

Retrieved on: 
Wednesday, June 29, 2022 - 6:48pm
Supply, Blood pressure, Glucose, Intention, Remote patient monitoring, GLOBE, Letter, Company, Tracker, HIPAA, Diabetes, Oxygen, TRCC, Private Securities Litigation Reform Act, SEC, Temperature, EKG, OTC Markets Group, Medical device

WALNUT CREEK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Traccom Inc. (OTC Pink: TRCC) (Company) is pleased to announce that the Company has signed a Supply Agreement Letter of Intent with Diabetic Direct, Inc. to be a primary supplier of remote patient monitoring devices with its Traccom MedicalPro device.

Key Points: 
  • WALNUT CREEK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Traccom Inc. (OTC Pink: TRCC) (Company) is pleased to announce that the Company has signed a Supply Agreement Letter of Intent with Diabetic Direct, Inc. to be a primary supplier of remote patient monitoring devices with its Traccom MedicalPro device.
  • Harry Steck, Chief Executive Officer of the Traccom, stated, "This Supply Agreement Letter of Intent represents a significant opportunity for the Company to gain a presence in this critical segment of the U.S. health care market that is comprised of 37 million diabetic patients.
  • The Company operates in the technology sector and has focused over the past two years on developing two break through products.
  • The Traccom Basic Tracker can be used by consumers who fly and check in their luggage with the airline.

Siemens launches Siemens Xcelerator - an open digital business platform to accelerate digital transformation

Retrieved on: 
Wednesday, June 29, 2022 - 4:13pm
Acquisition, Transport, CEO, Bentley, SAP, Atos, Industrial internet of things, Internet, Pandemic, Industry, Accenture, Ecosystem, Financial statement, Goal, SSOT, API, Software as a service, Digital, Automation, Partnership, Software, Building, Technology, NVIDIA, Siemens Healthineers, AWS, Partner, Solution, Xcelerator, AI, Maintenance, Information technology, IOT, Intention, Multimedia, Microsoft, Cryptocurrency, Network equipment, Video game console, Online shopping, Siemens Energy

Roland Busch, President and CEO of Siemens AG, said: "Siemens Xcelerator will make it easier than ever before for companies to navigate digital transformation faster and at scale.

Key Points: 
  • Roland Busch, President and CEO of Siemens AG, said: "Siemens Xcelerator will make it easier than ever before for companies to navigate digital transformation faster and at scale.
  • The open digital business platform creates value for participants by facilitating interactions and fostering innovation between multiple parties customers, partners, developers etc.
  • As a first step in this collaboration, the companies plan to connect Siemens Xcelerator, the open digital business platform and NVIDIA Omniverse, a platform for 3D-design and collaboration.
  • The launch of the Siemens Xcelerator platform is the logical next step in Siemens' digital strategy.

Greater Philadelphia Region Seeks ARPA-H Home

Retrieved on: 
Wednesday, June 29, 2022 - 4:00pm
Drexel University, Wistar Institute, Bangladesh Technical Education Board, FDA, Chamber, Patient, Coriell Institute for Medical Research, RNA transfection, GSK, Children's Hospital of Philadelphia, HHS, Jefferson Health, Research, Senior, Johnson & Johnson, COVID-19, Commerce, International airport, Atmosphere, ARPA, NIH, PHL, Temple University, Institute for Economic Competitiveness, Letter, DARPA, Hospital, Bristol Myers Squibb, Gene editing, University, AstraZeneca, Congress, Philadelphia International Airport, Vaccine, Intention, Pharmaceutical industry, Merck, Delaware Valley, Pfizer

PHILADELPHIA, June 29, 2022 /PRNewswire/ -- The Chamber of Commerce for Greater Philadelphia today announced the region's intention to seek to be the new home for a recently announced $1 billion federal agency, the Advanced Research Projects Agency for Health (ARPA-H), which is expected to be located outside of Washington D.C.  In a letter sent to the U.S. Health & Human Services Department Secretary Xavier Becerra and signed by business, civic, and elected officials, signers tout the region's expertise in cell & gene therapy and gene editing, its rank as one of the top eight life sciences markets in the U.S., and its deep scientific and medical ecosystem as reasons why this area stands out as the ideal location. The new agency, established by Congress earlier this year, will speed up biomedical and health cures and treatment by funding new and innovative research.

Key Points: 
  • "We feel that Greater Philadelphia's position as a global hub of research, talent, capital, and companies, combined with its second-to-none accessibility, give this region the power to forever transform how care is delivered to patients and essentially cure the incurable," the letter states.
  • "Today the Chamber is launching a multi-state, eleven-county regional effort to attract the new Advanced Research Projects Agency for Health to the Greater Philadelphia region," said Claire Marrazzo Greenwood, Executive Director and Senior Vice President of Economic Competitiveness for the Chamber.
  • The Philadelphia region has a long and deep track record of innovation.
  • To date, six FDA-approved cell & gene therapies have their origins in the region.

Titan Medical Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Retrieved on: 
Wednesday, June 29, 2022 - 3:31pm
Nasdaq, Surgeon, Panel, LinkedIn, TSX, GLOBE, Growth, US, Toronto Stock Exchange, Compliance, RAS, Calendar, Enos, TMD, Time, Twitter, News, Intention, Forward-looking statement, Motion, Medical device, Audit, Titan

In the event the company does not evidence compliance with the minimum bid price requirement during the 180-day grace period, it is expected that Nasdaq would notify the company that its shares are subject to delisting.

Key Points: 
  • In the event the company does not evidence compliance with the minimum bid price requirement during the 180-day grace period, it is expected that Nasdaq would notify the company that its shares are subject to delisting.
  • There can be no assurance that any such appeal would be successful or that the company would be able to evidence compliance with the terms of any extension that may be granted by the Panel.
  • The Nasdaq notification letter does not impact the company's compliance or listing status on the Toronto Stock Exchange.
  • Enos is a trademark of Titan Medical Inc.
    For more information, visit www.titanmedicalinc.com and connect with the company on Twitter, @TitanMedical and LinkedIn .

More than 425 SiriusXM Channels Now Available on Comcast's Entertainment Platforms

Retrieved on: 
Wednesday, June 29, 2022 - 3:01pm
Music, The Howard Stern Show, Annual report, Sirius XM, Life, Hall, Projection, Pandora, SIRI, FCC, COVID-19, Marketing, Failure, Xfinity Flex, Company, Radio, Industry, U.S. Securities and Exchange Commission, Office, Marvel Entertainment, Ecosystem, Catalog, Policy, Flex, Freakonomics Radio, Sport, Privacy, Security (finance), Private Securities Litigation Reform Act, Communication, Software, Comcast, Health, SEC, Human, NEW, List of halls and walks of fame, NASDAQ, Taste, Pod Save America, Government, News, Information technology, List of Sirius XM Radio channels, Intention, Collection, Entertainment, Mobile phone, Communications satellite, Risk management

NEW YORK, June 29, 2022 /PRNewswire/ -- SiriusXM announced today that its SXM App, which delivers more than 425 SiriusXM channels of the best in audio entertainment – Howard Stern, ad-free music, sports and more – is now available to tens of millions of Comcast customers nationwide on Xfinity X1, Xfinity Flex and XClass TV, giving its subscribers a new way to experience SiriusXM programming at home.

Key Points: 
  • Future enhancements to the SXM App experience on Comcast's platforms are expected to include access to SiriusXM's expansive video library.
  • "We're thrilled that the SXM App is now live across Comcast's entertainment platforms, enabling its customers to easily get our great streaming features and our full lineup of audio entertainment," said Joe Verbrugge, Chief Commercial Officer, SiriusXM.
  • "SiriusXM offers an extensive array of content and is a great addition to the growing catalog of apps available across our entertainment platforms," said Sudhir Muralidhar, Vice President, App Ecosystem, Comcast.
  • SiriusXM content available on Comcast will mirror what is available to subscribers streaming on the SXM App, based on their subscription.